5FWC
| Human Spectrin SH3 domain D48G, E7A, K60A | Descriptor: | 1,2-ETHANEDIOL, AMMONIUM ION, SPECTRIN ALPHA CHAIN, ... | Authors: | Gallego, P, Navarro, S, Ventura, S, Reverter, D. | Deposit date: | 2016-02-12 | Release date: | 2016-12-28 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (1.4 Å) | Cite: | Human Spectrin SH3 Domain D48G, E7A, K60A To be Published
|
|
5FW9
| Human Spectrin SH3 domain D48G, E7Y, K60Y | Descriptor: | SPECTRIN ALPHA CHAIN, NON-ERYTHROCYTIC 1 | Authors: | Gallego, P, Navarro, S, Ventura, S, Reverter, D. | Deposit date: | 2016-02-12 | Release date: | 2016-12-28 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (1.55 Å) | Cite: | Human Spectrin SH3 Domain D48G, E7Y, K60Y To be Published
|
|
5FWB
| Human Spectrin SH3 domain D48G, E7F, K60F | Descriptor: | SPECTRIN ALPHA CHAIN, NON-ERYTHROCYTIC 1 | Authors: | Gallego, P, Navarro, S, Ventura, S, Reverter, D. | Deposit date: | 2016-02-12 | Release date: | 2016-12-28 | Last modified: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.5 Å) | Cite: | Human Spectrin SH3 Domain D48G, E7F, K60F To be Published
|
|
6RO9
| Human spectrin SH3 domain D48G, E7V, K60V | Descriptor: | Spectrin alpha, non-erythrocytic 1 | Authors: | Reverter, D, Navarro, S, Ventura, S. | Deposit date: | 2019-05-10 | Release date: | 2020-06-03 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.814 Å) | Cite: | Human spectrin SH3 domain D48G, E7V, K60V To Be Published
|
|
6FWW
| GFP/KKK. A redesigned GFP with improved solubility | Descriptor: | Green fluorescent protein | Authors: | Varejao, N, Lascorz, J, Gil-Garcia, M, Diaz-Caballero, M, Navarro, S, Ventura, S, Reverter, D. | Deposit date: | 2018-03-07 | Release date: | 2018-08-01 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.131 Å) | Cite: | Combining Structural Aggregation Propensity and Stability Predictions To Redesign Protein Solubility. Mol. Pharm., 15, 2018
|
|
8BQ3
| |
6EXZ
| Crystal structure of Mex67 C-term | Descriptor: | FORMIC ACID, mRNA export factor MEX67 | Authors: | Mohamad, N, Bravo, J. | Deposit date: | 2017-11-10 | Release date: | 2018-11-21 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | Mip6 binds directly to the Mex67 UBA domain to maintain low levels of Msn2/4 stress-dependent mRNAs. Embo Rep., 2019
|
|
7QC5
| Crystal structure of human wild type transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3-fluoro-5-hydroxyphenyl)methanone compound | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-[3-nitro-4,5-bis(oxidanyl)phenyl]methanone, Transthyretin | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | Deposit date: | 2021-11-22 | Release date: | 2022-11-30 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (1.2 Å) | Cite: | Development of a Highly Potent Transthyretin Amyloidogenesis Inhibitor: Design, Synthesis, and Evaluation. J.Med.Chem., 65, 2022
|
|
7T6G
| Truncated Ac-AIP-2 | Descriptor: | Truncated Ac-AIP-2 | Authors: | Daly, N.L, Cobos, C. | Deposit date: | 2021-12-13 | Release date: | 2022-10-19 | Last modified: | 2024-05-15 | Method: | SOLUTION NMR | Cite: | Peptides derived from hookworm anti-inflammatory proteins suppress inducible colitis in mice and inflammatory cytokine production by human cells. Front Med (Lausanne), 9, 2022
|
|
5VFW
| |
5VAV
| |
8PM9
| Crystal structure of human wild type transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone, Transthyretin | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | Deposit date: | 2023-06-28 | Release date: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.85 Å) | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties. Eur.J.Med.Chem., 261, 2023
|
|
8PM8
| V30M Transthyretin structure in complex with Tolcalpone | Descriptor: | Tolcapone, Transthyretin | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | Deposit date: | 2023-06-28 | Release date: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.57 Å) | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties. Eur.J.Med.Chem., 261, 2023
|
|
8PMO
| Crystal structure of human V122I transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone, Transthyretin | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | Deposit date: | 2023-06-29 | Release date: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.24 Å) | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties. Eur.J.Med.Chem., 261, 2023
|
|
8PMA
| Crystal structure of human V30M transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) | Descriptor: | (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone, Transthyretin | Authors: | Varejao, N, Pinheiro, F, Pallares, I, Ventura, S, Reverter, D. | Deposit date: | 2023-06-28 | Release date: | 2024-05-08 | Method: | X-RAY DIFFRACTION (1.2 Å) | Cite: | PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties. Eur.J.Med.Chem., 261, 2023
|
|
7L2G
| |